| Old Articles: <Older 6611-6620 Newer> |
|---|
 |
The Motley Fool
August 24, 2010
Brian Orelli |
One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well.   |
The Motley Fool
August 24, 2010
Brian Orelli |
Disaster in Medical-Device Land Industry bellwether Medtronic is forecasting a nasty storm. |
The Motley Fool
August 24, 2010
David Meier |
Could Bristol-Myers Squibb Be a Multibagger? Strong returns on equity can generate powerful returns for shareholders. |
The Motley Fool
August 24, 2010
Matt Koppenheffer |
How Much Is Johnson & Johnson Worth? Is Johnson & Johnson's stock on sale? |
The Motley Fool
August 24, 2010
David Meier |
Could Amgen Be a Multibagger? Strong returns on equity can generate powerful shareholder returns. |
The Motley Fool
August 24, 2010
David Meier |
Can Express Scripts Produce Big Returns? Express Scripts generates incredible returns on equity. Let's see how they do it. |
The Motley Fool
August 24, 2010
David Meier |
Can McKesson Produce Big Returns? McKesson uses its production advantage -- high asset turnover and reasonable leverage -- to generate very attractive returns on equity for shareholders. |
The Motley Fool
August 24, 2010
Travers & Jayson |
Will Valeant Pharmaceuticals Burn You? How well has Valeant Pharmaceuticals International tapped the capital markets? Here's a visual summary of the past few years |
The Motley Fool
August 24, 2010
Selena Maranjian |
A Dying Industry to Die For The death-care sector is sad -- but lucrative. |
The Motley Fool
August 24, 2010
Eric Dutram |
Tuesday's ETF to Watch: Medical Devices ETF (IHI) Medtronic reports earnings today; keep your eye on this medical devices ETF. |
| <Older 6611-6620 Newer> Return to current articles. |
